About ProciseDx
ProciseDx is a Healthcare company based in San Diego (United States) founded in 2018, and was acquired by Biosynex in June 2023. Point-of-care diagnostic devices for immunoassay tests are provided to clinicians. ProciseDx has raised $8.96 million across 3 funding rounds from investors including Nestlé Health Science and Biosynex. Its chief executive, as recorded, is Larry Mimms. ProciseDx offers products and services including Drug Monitoring Assays and ProciseDx Platform. Its focus areas include Diversified Diagnostics, Tests and Point Of Care. Its competitors include LumiraDx, LightDeck Diagnostics and Abaxis; 2 of its 3 listed competitors have raised funding.
Company details
ProciseDx was established in 2018 in San Diego, United States, within the healthcare diagnostics sector. A point-of-care device is supplied to professionals for clinical analysis. Proprietary Lumiphore technology is employed to measure patient samples, including blood, urine, and stool, in immunoassay procedures. Results from the device are used by healthcare providers to support diagnosis and treatment decisions in various settings.
- Headquarters San Diego, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website procisedx.com
- Social LinkedIn X
- Acquired by Biosynex (Jun 2023)
- Total Equity Funding$8.96M (USD)
in 3 rounds
- Latest Funding Round$13M (USD), Debt – Convertible
Jul 2021
- InvestorsNestlé Health Science
& 1 more
- Acquired byBiosynex
(Jun 2023)
Products & Services of ProciseDx
ProciseDx offers a comprehensive portfolio of products and services, including Drug Monitoring Assays and ProciseDx Platform.
Provide quick, accurate drug level measurements from blood samples.
Enables immediate clinical decisions with quantitative immunoassays.
Funding Insights of ProciseDx
ProciseDx has successfully raised a total of $8.96M across 3 strategic funding rounds. The most recent funding activity was a Debt – Convertible round of $13 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.96M
- Total Rounds 3
- Last Round Debt – Convertible — $13M
- First Round $2M
(Jul 2020)
- Investors Count 2
All 3 funding rounds of ProciseDx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2021 | $13M | Debt – Convertible | – | Nestlé Health Science | |
| Jul 2020 | $8.96M | Series A | – | Biosynex | – |
| Jul 2020 | $2M | Debt – Conventional | – | – | – |
2 investors in total: 2 institutional.
Investors in ProciseDx
ProciseDx has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Nestlé Health Science and Biosynex.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Nutritional dietary supplements are provided for health and wellness needs. | 2011 | nestlehealthscience.com | Epalinges, Switzerland | |
Professional rapid diagnostic tests for diseases are manufactured by Biosynex. | 2005 | biosynex.com | Strasbourg, France |
Investor details for ProciseDx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ProciseDx
1 people are tracked at ProciseDx (1 in leadership).
| Name | Role | Group |
|---|---|---|
Larry Mimms | CEO | Leadership |
Complete people profiles for ProciseDx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ProciseDx
4 dated milestones of ProciseDx across 5 years, from founding to its latest funding, stage changes and deals.
- Founded ProciseDx is founded.
- Funding First funding round of $2.0M.
- Funding Latest funding round, Debt – Convertible, of $13.0M.
- Exit Acquired by Biosynex.
Competitors of ProciseDx
ProciseDx has 3 listed competitors in our database, 2 of them funded. They include LumiraDx, LightDeck Diagnostics and Abaxis.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lumiradx.com | 2014 | Waltham, United States | $703.91M | Cloud based diagnostics platform for point of care diagnosing | ||
| lightdeckdx.com | 2009 | Boulder, United States | $57.02M | Point-of-care diagnostic devices for multiplex assays are developed. | ||
| abaxis.com | 1989 | California, United States | 564 | Diagnostics company offering a comprehensive line of on-site diagnostic instruments and rapid tests |
Detailed competitors of ProciseDx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Diagnostics & Lab Tech
3 companies that operate in the same segment as ProciseDx (Diagnostics & Lab Tech) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
At-home health tests for biomarkers, nutrition, and hormone analysis. | 2014 | Austin, Texas, United States | USD 330 M | 336 | ||
Blood testing services are offered using finger-prick microsamples. | 2017 | Austin, Texas, United States | USD 37.7 M | |||
Manufactures clinical diagnostic test kits | 1971 | Irvine, California, United States | USD 4.45 M | 54 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Procisedx
Complete news archive for ProciseDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ProciseDx
ProciseDx was founded in 2018 and raised its 1st funding round 2 years after it was founded.
ProciseDx is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Larry Mimms is the CEO of ProciseDx, as recorded in our data.
ProciseDx is a funded company, having raised a total of $8.96M across 3 funding rounds to date. The company's 1st funding round was a Series A of $8.96M, raised on Jul 2020.
ProciseDx was established in 2018 in San Diego, United States, within the healthcare diagnostics sector. A point-of-care device is supplied to professionals for clinical analysis. Proprietary Lumiphore technology is employed to measure patient samples, including blood, urine, and stool, in immunoassay procedures. Results from the device are used by healthcare providers to support diagnosis and treatment decisions in various settings.
ProciseDx's top competitors include LumiraDx, Abaxis and LightDeck Diagnostics.
ProciseDx offers Drug Monitoring Assays and ProciseDx Platform.
ProciseDx has 2 investors. Key investors include Nestlé Health Science, and Biosynex.
Yes. ProciseDx was acquired by Biosynex in June 2023.